As 2024 was drawing to a close, OpenAI CEO Sam Altman faced two major problems. He wasn’t getting enough server capacity from Microsoft, his company’s biggest backer, to stay ahead of rivals developing artificial intelligence.
Latin Times on MSN8h
Oracle Founder Larry Ellison Praises AI Surveillance State in Video Clip Resurfaced After Trump AI Infrastructure Announcement: 'Citizens Will Be On Their Best Behavior'The billionaire co-founder of tech company Oracle has expressed excitement about the new era of surveillance he believes will be made possible by AI.
Oracle founder Larry Ellison said the Stargate project, a joint venture with OpenAI and Softbank, will help to fuel the development of a cancer vaccine.
At the launch of Stargate Project, Oracle's Ellison said that AI could assist in identifying the cancer fragments early through a simple blood test, followed by gene sequencing of the tumour
WASHINGTON – General Atlantic CEO Bill Ford said on Wednesday that a deal would get done to save TikTok in the U.S. after President Donald Trump signed an executive order that halted a ban on the app for 75 days.
Latin Times on MSN1h
Trump Says He 'Doesn't Know' If AI Companies Can Fund Massive Plan 1 Day After Announcing ItPresident Trump admitted he is unsure whether the coalition of AI giants leading the $500 billion Stargate Project has the resources to fully realize it.
What is Larry Ellison's net worth in 2025? What are the secrets behind the 80-year-old from New York City, who is currently considered the second-wealthiest man in the world behind
Tensions between technology leaders Elon Musk and OpenAI CEO Sam Altman were on full display this week after the Tesla CEO slammed the new artificial intelligence (AI) infrastructure project,
The tech billionaires have a rocky history, and Musk's comments about funding for the project, which could attract $500 billion prompted a pointed response from OpenAI leader Altman.
Explore the pros and cons of the first round of technology developments from President Trump's first week in office. What impact will his bold tech moves have?
MRNA’s first problem is the lack of near-term catalysts beyond infectious disease vaccines. The stock often swings on disease outbreaks, such as H5N1 avian flu last year, but this is unlikely to represent a sustainable long-term revenue generator.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback